Verastem (VSTM) Stock Price

Verastem Price

NASDAQ·CLOSED
6.33
​
Market closed

Over the last 7 years Verastem grew revenue by 2.1% annually, reaching 30.91 M USD. For Verastem, the net margin of -677.6% is down versus -76.5% a few years ago. The consensus 12-month price target for Verastem is 13.50 USD, about 113.3% above where the stock trades today. Of 16 analysts, 15 rate the stock a buy — an overall Buy consensus.

Verastem stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Verastem business model & stock analysis

Verastem Oncology develops and commercializes oncology drugs to improve cancer patient survival and quality of life. The company focuses on defactinib, an oral small molecule inhibitor of FAK and PYK2, and VS-6766, a RAF/MEK pathway inhibitor. Defactinib is being evaluated for combination therapy in solid tumors, while VS-6766 blocks MEK kinase activity and RAF phosphorylation. Verastem conducts clinical trials for cancers with limited treatment options including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer, and pancreatic cancer. The company markets and develops these products for healthcare providers and patients in the oncology segment. Verastem Oncology targets cancer patients requiring new treatment options, particularly in underserved areas like pancreatic cancer and mesothelioma. Its products are designed to address unmet medical needs in oncology through targeted therapies. Verastem generates revenue through the commercialization of defactinib and VS-6766 once approved. The company's business model relies on developing drugs for cancer treatment, with clinical trials focused on improving outcomes for patients with limited therapeutic options. Revenue streams come from product sales and potential partnerships for drug development and commercialization.

Frequently asked questions about Verastem

Analysts currently set an average price target of 13.83 USD for the Verastem stock (median: 13.50 USD), implying +118.5 % versus the latest price. The consensus is based on 16 analyst ratings.

16 analysts currently rate the Verastem stock: 15 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Verastem to generate revenue of 107.72 M USD and earnings per share of -1.76 USD.

Converted at the current exchange rate, the Verastem share trades at 5.77 EUR (6.33 USD).

The Verastem share (VSTM) is listed on 5 stock exchanges, including: NASDAQ (VSTM), London (0LOV.L), Frankfurt (2VS.F), München (2VS.MU), Düsseldorf (2VS.DU).

The expected revenue of Verastem is 107.72 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Verastem is -146.59 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Verastem is currently -3.60. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Verastem stock.

The price-to-sales ratio (P/S) of Verastem is currently 4.90. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Verastem stock.

The Eulerpool Quality Score for Verastem is 6/10.

The ISIN of Verastem is US92337C2035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Verastem is A1JTPU. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Verastem is VSTM. The ticker symbol is used to trade Verastem shares on the stock exchange.

Fair ValueTerminal
6.65 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
303,078.43 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website verastem.com
Currency
USD
Initial public offering
Nov 8, 2011
ISIN
US92337C2035
Cusip
92337C104
Sedol
B4Z1Y92
Market capitalization
488.36 M USDSmall Cap
52-Week Range
PEG
0.06
P/E ratio
P/Ee 2026
-3.60
P/Ee 2027
-4.41
P/Ee 2028
-3.26
P/Ee 2029
-5.01
P/Ee 2030
-42.45
P/Se
4.90
EV/EBIT
—
P/B Ratio
8.54
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-156.25 %
Last updated Nov 22, 2026, 3:41 AM

Verastem Ticker

DÜSSELDORF · 2VS.DUFRANKFURT · 2VS.FLONDON · 0LOV.LMUNICH · 2VS.MUNASDAQ · VSTM

All fundamentals and in-depth analysis of Verastem

Our stock analysis for Verastem stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Verastem. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.